Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KALA BIO, Inc. - Common Stock (NQ:KALA)

0.4428 +0.0438 (+10.98%)
Streaming Delayed Price Updated: 2:15 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about KALA BIO, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
KALA BIO Settles Approximately $10.6 million of Debt
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companies 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces Chief Executive Officer Transition
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces $10,750,000 Private Placement
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces $12,500,000 Private Placement
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.